Our Take
The pitch for AI co-scientists has outrun the evidence that they solve real problems in the lab.
Why it matters
Biotech teams are evaluating expensive AI tools based on vendor claims rather than field validation. Knowing what actually works saves budget and prevents wasted cycles on overstated capabilities.
Do this week
Research teams: Before licensing an AI co-scientist tool, ask the vendor for peer-reviewed publications or named customer benchmarks showing the specific workflow it improves (hypothesis generation, experimental design, data analysis) and by how much.
STAT News Questions AI Co-Scientist Utility
Brittany Trang, who covers AI in health and medicine for STAT, published an investigation into whether AI co-scientist tools deliver value to working scientists. The piece challenges marketing claims that position these tools as genuine research collaborators, concluding that current offerings may not yet justify adoption.
The investigation emerged from STAT's Breakthrough Summit West in San Francisco, where Trang spoke with panels of health-tech leaders and researchers about real-world deployment. The article is framed around a core question: does this actually work, and for whom?
STAT positions this as part of its "AI Prognosis" newsletter, a subscriber-focused column that evaluates AI claims in medicine and biotech against evidence rather than marketing language.
Vendors Are Ahead of Validation
AI co-scientist tools are being sold to biotech and pharma teams as labor savers for hypothesis generation, experimental design, and data interpretation. The problem: most vendors publish no independent benchmarks showing they actually accelerate discovery or reduce researcher time on specific tasks.
Labs making purchasing decisions today have little to go on beyond product demos and internal trials. Without peer-reviewed performance data or customer case studies with measurable outcomes (e.g., "reduced hypothesis iteration cycles by X percent"), teams risk spending on tools that sound good in pitch decks but don't move the needle in practice.
This gap matters because biotech budgets are constrained, and opportunity cost is real. Scientist time spent testing unproven tools is time not spent on actual experiments.
What Scientists Should Do Before Buying
Demand specificity from vendors. "Helps with analysis" is not a claim; "cuts time to statistical significance on RNA-seq workflows from 8 hours to 2 hours" is. Ask for named customers willing to share results. Request peer-reviewed papers if they exist. Run a time-boxed pilot on one real workflow and measure the delta in hours or cost per experiment.
If a vendor cannot produce independent validation or customer references, treat it as experimental software, not a trusted collaborator.